全文获取类型
收费全文 | 4728篇 |
免费 | 29篇 |
国内免费 | 3篇 |
专业分类
儿科学 | 82篇 |
妇产科学 | 6篇 |
基础医学 | 48篇 |
口腔科学 | 3篇 |
临床医学 | 152篇 |
内科学 | 4108篇 |
皮肤病学 | 2篇 |
神经病学 | 16篇 |
特种医学 | 50篇 |
外科学 | 171篇 |
综合类 | 53篇 |
预防医学 | 34篇 |
药学 | 32篇 |
中国医学 | 2篇 |
肿瘤学 | 1篇 |
出版年
2023年 | 24篇 |
2022年 | 31篇 |
2021年 | 121篇 |
2020年 | 61篇 |
2019年 | 380篇 |
2018年 | 295篇 |
2017年 | 87篇 |
2016年 | 16篇 |
2015年 | 36篇 |
2014年 | 102篇 |
2013年 | 65篇 |
2012年 | 76篇 |
2011年 | 93篇 |
2010年 | 89篇 |
2009年 | 78篇 |
2008年 | 95篇 |
2007年 | 91篇 |
2006年 | 70篇 |
2005年 | 66篇 |
2004年 | 66篇 |
2003年 | 38篇 |
2002年 | 5篇 |
2001年 | 1篇 |
2000年 | 2篇 |
1999年 | 1篇 |
1998年 | 3篇 |
1994年 | 3篇 |
1993年 | 1篇 |
1991年 | 3篇 |
1989年 | 2篇 |
1988年 | 3篇 |
1986年 | 1篇 |
1985年 | 119篇 |
1984年 | 435篇 |
1983年 | 438篇 |
1982年 | 311篇 |
1981年 | 260篇 |
1980年 | 211篇 |
1979年 | 217篇 |
1978年 | 183篇 |
1977年 | 112篇 |
1976年 | 129篇 |
1975年 | 121篇 |
1974年 | 120篇 |
1973年 | 99篇 |
排序方式: 共有4760条查询结果,搜索用时 15 毫秒
61.
《The Journal of clinical investigation》2015,125(6):2317-2334
Mast cells (MCs) have been identified in various tumors; however, the role of these cells in tumorigenesis remains controversial. Here, we quantified MCs in human and murine malignant pleural effusions (MPEs) and evaluated the fate and function of these cells in MPE development. Evaluation of murine MPE-competent lung and colon adenocarcinomas revealed that these tumors actively attract and subsequently degranulate MCs in the pleural space by elaborating CCL2 and osteopontin. MCs were required for effusion development, as MPEs did not form in mice lacking MCs, and pleural infusion of MCs with MPE-incompetent cells promoted MPE formation. Once homed to the pleural space, MCs released tryptase AB1 and IL-1β, which in turn induced pleural vasculature leakiness and triggered NF-κB activation in pleural tumor cells, thereby fostering pleural fluid accumulation and tumor growth. Evaluation of human effusions revealed that MCs are elevated in MPEs compared with benign effusions. Moreover, MC abundance correlated with MPE formation in a human cancer cell–induced effusion model. Treatment of mice with the c-KIT inhibitor imatinib mesylate limited effusion precipitation by mouse and human adenocarcinoma cells. Together, the results of this study indicate that MCs are required for MPE formation and suggest that MC-dependent effusion formation is therapeutically addressable. 相似文献
62.
63.
Mai Kimura Takashi Kohno Takashi Kawakami Masaharu Kataoka Takahiro Hiraide Hidenori Moriyama Sarasa Isobe Toshimitsu Tsugu Yuji Itabashi Mitsushige Murata Shinsuke Yuasa Keiichi Fukuda 《The Canadian journal of cardiology》2019,35(2):193-198
Background
There is no consensus on the length of hospital stay (LOHS) and post-interventional management after balloon pulmonary angioplasty (BPA) in patients with chronic thromboembolic pulmonary hypertension (CTEPH). We examined temporal trends with respect to LOHS and requirement for intensive care for BPA and their relationship with the incidence of BPA-related complications.Methods
From November 2012 to September 2017, a total of 123 consecutive patients with CTEPH who underwent BPA were enrolled (age: 66.0 [54.0 to 74.0], World Health Organization [WHO] functional class II/III/IV; 27/88/8). Patients were divided for analysis into 3 groups according to the date of their first BPA: early-, middle-, and late-phase groups.Results
Mean pulmonary arterial pressure decreased from 36.0 (29.0 to 45.0) to 20.0 (16.0 to 22.0) mm Hg after BPA (P < 0.001). The LOHS was 41.0 (31.0 to 54.0) days in total including all sessions and 6.6 (6.0 to 7.9) days/session. Despite no significant differences in age, baseline hemodynamics, and laboratory data among the 3 groups, there was a significant reduction in LOHS (7.9 [7.0 to 9.5], 6.5 [6.1 to 7.3], 6.0 [5.3 to 6.5] days/session, P < 0.001) and use of intensive/high care unit (100%, 93%, 46%, P < 0.001). The reduction in LOHS and intensive/high care unit use did not affect the occurrence of BPA-related complications.Conclusions
Increasing experience with BPA was associated with a reduction in LOHS and the use of intensive/high care unit, but no change was noted in the rate of BPA-related complications. These findings suggest that the reduction in both LOHS and use of the intensive care unit for BPA is feasible and does not jeopardize the safety of the procedure. 相似文献64.
65.
66.
67.
Dominic A.M.J. Theuns Nick Van Boven Beat A. Schaer Tim Hesselink Maximo Rivero-Ayerza Victor Umans Christian Sticherling Marcoen F. Scholten Frederik Verbrugge Felix Zijlstra 《Journal of cardiac failure》2019,25(10):812-818
BackgroundThe beneficial effects of a cardiac resynchronization defibrillator (CRT-D) in patients with heart failure, low left ventricular ejection fraction (LVEF), and wide QRS have clearly been established. Nevertheless, mortality remains high in some patients. The aim of this study was to develop and validate a risk score to identify patients at high risk for early mortality who are implanted with a CRT-D.Methods and ResultsFor predictive modelling, 1282 consecutive patients from 5 centers (74% male; median age 66 years; median LVEF 25%; New York Heart Association class III–IV 60%; median QRS-width 160 ms) were randomly divided into a derivation and validation cohort. The primary endpoint is mortality at 3 years. Model development was performed using multivariate logistic regression by checking log likelihood, Akaike information criterion, and Bayesian information criterion. Model performance was validated using C statistics and calibration plots. The risk score included 7 independent mortality predictors, including myocardial infarction, LVEF, QRS duration, chronic obstructive pulmonary disease, chronic kidney disease, hyponatremia, and anemia. Calibration-in-the-large was suboptimal, reflected by a lower observed mortality (44%) than predicted (50%). The validated C statistic was 0.71 indicating modest performance.ConclusionA risk score based on routine, readily available clinical variables can assist in identifying patients at high risk for early mortality within 3 years after CRT-D implantation. 相似文献
68.
Protein-losing enteropathy (PLE) is a chronic condition involving multiple organ systems that may develop any time following Fontan completion. The pathogenesis of PLE is complex and multifactorial. Chronic venous hypertension, low cardiac output, and abnormal lymphatics may all play a role in the pathogenesis of PLE. Common signs and symptoms include chronic diarrhea, abdominal pain, and ascites. Diagnosis is based on the presence of signs and symptoms in addition to hypoalbuminemia and elevated stool alpha 1 antitrypsin. Early identification and a comprehensive approach to evaluation and treatment are important, as they may affect survival. The initial evaluation should include cardiac catheterization for hemodynamic assessment. Although an evidence base for treatment is lacking, various medical, interventional, and surgical approaches have been described with variable degrees of success. Commonly used therapies include nutritional support, diuretics, subcutaneous unfractionated heparin, budesonide, and sildenafil. Limited data exist for Fontan conversion or takedown. Assessment for heart transplantation should be considered. PLE mortality is high—approximately 50%—but may be mitigated by aggressive investigation and management. The evolving understanding of the role of lymphatics in the pathophysiology of PLE and the emerging role of interventional lymphatic procedures may further improve outcomes in this patient population. 相似文献
69.
70.